Demarcating the benefits of hybrid closed loop therapy in pregnant women with type 1 diabetes
- PMID: 38697181
- DOI: 10.1016/S2213-8587(24)00104-9
Demarcating the benefits of hybrid closed loop therapy in pregnant women with type 1 diabetes
Conflict of interest statement
HRM is a member of the UK and European Medtronic Scientific Advisory Boards and reports receiving speaker honoraria from Dexcom, Abbott Diabetes Care, Novo Nordisk, and Ypsomed. EMS reports receiving speaker honoraria from Abbott Diabetes Care.
Comment on
-
Comparing advanced hybrid closed loop therapy and standard insulin therapy in pregnant women with type 1 diabetes (CRISTAL): a parallel-group, open-label, randomised controlled trial.Lancet Diabetes Endocrinol. 2024 Jun;12(6):390-403. doi: 10.1016/S2213-8587(24)00089-5. Epub 2024 Apr 30. Lancet Diabetes Endocrinol. 2024. PMID: 38697182 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
